Werewolf Therapeutics(US:HOWL)2025-11-04 12:07Clinical Trials - WTX-124 received Fast Track Designation from the FDA for treating locally advanced or metastatic cutaneous melanoma, with interim data and feedback expected in Q4 2025 [3] - Enrollment in the Phase 1/1b clinical trial for WTX-124 is expected to be completed by Q1 2026, with a recommended dose of 18 mg administered intravenously every two weeks [3] - WTX-330 is actively enrolling in a Phase 1b/2 clinical trial, with an update expected in Q4 2025 [8] - The company plans to nominate a differentiated target candidate for WTX-1011 by year-end 2025 [2] Financial Performance - Cash and cash equivalents as of September 30, 2025, were $65.7 million, down from $77.6 million as of June 30, 2025, sufficient to fund operations into Q4 2026 [8] - Research and development expenses for Q3 2025 were $11.6 million, a decrease from $12.5 million in Q3 2024 [8] - General and administrative expenses for Q3 2025 were $4.1 million, down from $4.6 million in Q3 2024 [8] - Net loss for Q3 2025 was $16.4 million, compared to a net loss of $16.7 million in Q3 2024 [8] - Total operating expenses for Q3 2025 were $15.7 million, compared to $17.1 million in Q3 2024 [13] - Total stockholders' equity as of September 30, 2025, was $29.6 million, down from $73.4 million as of December 31, 2024 [15]